在牛皮患者中切换生物剂:系统性审查和元分析
LiHong Zhang1,2, XiTong Zhao1,2, WenChao Li1,2
1Dermatology Hospital of Shandong First Medical University, Jinan, P.R. China.
The Journal of dermatological treatment
|June 23, 2025
概括
与类间切换相比,对于牛皮的类内生物切换提供了优越的短期结果. 这两种策略都显示出长期的疗效和安全性,对于每种切换类型都更喜欢特定的药物.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 系统审查是系统的审查.
背景情况:
- 牛皮的治疗经常涉及生物疗法.
- 在生物治疗之间切换通常是必要的.
- 有限的研究存在于类内与类间的生物切换策略.
研究的目的:
- 在牛皮患者中,比较intraclass与interclass生物切换的疗效和安全性.
- 为了确定不同切换策略的首选生物制剂.
主要方法:
- 按照PRISMA指南进行系统审查和元分析.
- 在PubMed和EMBASE搜索了有关牛皮的生物切换研究.
- 包括19篇与679名患者的出版物.
主要成果:
- 班内切换 (519名患者) 在12周内显示出明显更高的牛皮区域和严重性指数 (PASI) 75的成就,而不是班间切换 (139名患者).
- 在16-52周后,PASI75的比例在类内和类间切换组之间是可比的.
- 特定的药物,如阿达利穆马布,ixekizumab和risankizumab被指出为类内转换,而guselkumab被强调为类间转换.
结论:
- 课内生物切换在牛皮治疗中显示出优越的短期疗效.
- 课内和课外切换策略对于长期的牛皮管理是有效和安全的.
- 亚达利穆马布,伊克齐祖马布和里桑基祖马布最好用于内部转换;古塞尔库马布用于类间过渡.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210
Antidepressant Drugs: MAOIs and Other Agents
378
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
378
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K


